В. Б. Матвеев

16.3k total citations · 5 hit papers
184 papers, 7.4k citations indexed

About

В. Б. Матвеев is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Surgery. According to data from OpenAlex, В. Б. Матвеев has authored 184 papers receiving a total of 7.4k indexed citations (citations by other indexed papers that have themselves been cited), including 131 papers in Pulmonary and Respiratory Medicine, 50 papers in Molecular Biology and 41 papers in Surgery. Recurrent topics in В. Б. Матвеев's work include Renal cell carcinoma treatment (66 papers), Prostate Cancer Treatment and Research (57 papers) and Renal and related cancers (28 papers). В. Б. Матвеев is often cited by papers focused on Renal cell carcinoma treatment (66 papers), Prostate Cancer Treatment and Research (57 papers) and Renal and related cancers (28 papers). В. Б. Матвеев collaborates with scholars based in Russia, United States and United Kingdom. В. Б. Матвеев's co-authors include Axel Heidenreich, Steven Joniau, M. Bolla, F. Zattoni, Joaquim Bellmunt, Nicolas Mottet, Thomas Wiegel, Hans Peter Schmid, Gunnar Aus and Theodorus van der Kwast and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

В. Б. Матвеев

152 papers receiving 7.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

EAU Guidelines on Prostate Cancer

2007 2.4k citations В. Б. Матвеев et al. profile →
EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent—Update 2013

2013 1.5k citations В. Б. Матвеев et al. profile →
EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Treatment of Clinically Localised Disease

2010 1.2k citations В. Б. Матвеев et al. profile →
Guidelines on Prostate Cancer

2013 438 citations В. Б. Матвеев et al. profile →
Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma

2021 183 citations David F. McDermott, Jae‐Lyun Lee et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by В. Б. Матвеев

Since Specialization

Citations

This map shows the geographic impact of В. Б. Матвеев's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by В. Б. Матвеев with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites В. Б. Матвеев more than expected).

Fields of papers citing papers by В. Б. Матвеев

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by В. Б. Матвеев. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by В. Б. Матвеев. The network helps show where В. Б. Матвеев may publish in the future.

Co-authorship network of co-authors of В. Б. Матвеев

This figure shows the co-authorship network connecting the top 25 collaborators of В. Б. Матвеев. A scholar is included among the top collaborators of В. Б. Матвеев based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with В. Б. Матвеев. В. Б. Матвеев is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Solitary fibrous tumor of the prostate: clinical case and literature review 2024 ·Cancer Urology ·(unknown), (unknown), (unknown), (unknown), (unknown), В. Б. Матвеев	0
2	1836P Blood based biomarkers identify metastatic castration-resistant prostate cancer (mCRPC) with the greatest benefit from continuing enzalutamide (ENZ) beyond progression in combination with docetaxel (Doc): A pre-specified biomarker study of the phase IIIb PRESIDE trial 2023 ·Annals of Oncology ·(unknown), Daniel Wetterskog, (unknown), Francesco Orlando, Anuradha Jayaram, (unknown), (unknown), (unknown), Kenneth K. Iwata, (unknown), (unknown), Lennart Åström, В. Б. Матвеев, Adil Esen, Susan Feyerabend, Elżbieta Senkus, Sumati Gupta, Axel S. Merseburger, Francesca Demichelis, Gerhardt Attard	1
3	Рак предстательной железы 2023 ·Malignant tumours ·Dmitry Nosov, М. И. Волкова, (unknown), (unknown), (unknown), В. Б. Матвеев, (unknown), Тимур Митин	1
4	Prognostic significance of sPD-1/sPD-L1 in renal cancer depending on the phenotype of tumor and stromal cells 2022 ·Cancer Urology ·О. В. Ковалева, Alexei Gratchev, (unknown), (unknown), И. С. Стилиди, В. Б. Матвеев, Н. Е. Кушлинский	1
5	Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma breakdown → 2021 ·Journal of Clinical Oncology ·David F. McDermott, Jae‐Lyun Lee, Marek Ziobro, Cristina Suárez, (unknown), В. Б. Матвеев, Paweł Wiechno, Rustem Gafanov, Piotr Tomczak, Frédéric Pouliot, Frede Donskov, B. Yа. Alekseev, Sang Joon Shin, Georg A. Bjarnason, Daniel Castellano, Rachel Kloss Silverman, Rodolfo F. Perini, Charles Schloss, Michael B. Atkins	183
6	The HPV and p63 Status in Penile Cancer Are Linked with the Infiltration and Therapeutic Availability of Neutrophils 2020 ·Molecular Cancer Therapeutics ·(unknown), (unknown), (unknown), Gilles Gasparoni, (unknown), В. Б. Матвеев, (unknown), Alexey Pryalukhin, Arndt Hartmann, Carol‐Immanuel Geppert, Hagen Loertzer, Heiko Wunderlich, Carsten Maik Naumann, Holger Kalthoff, Kerstin Junker, Sigrun Smola, Stefan Lohse	8
7	Clinical implication of kidney injury molecule (KIM-1) in blood plasma of renal-cell cancer patients 2020 ·SHILAP Revista de lepidopterología ·Е. С. Герштейн, (unknown), (unknown), (unknown), (unknown), В. Б. Матвеев, (unknown)	1
8	Prostate-specific antigen is a predictor of the efficacy of salvage radiation therapy in patients with recurrent prostate cancer after radical prostatectomy 2019 ·SHILAP Revista de lepidopterología ·(unknown), С. И. Ткачев, В. Б. Матвеев, (unknown)	0
9	Changing paradigm of immunooncology in advanced kidney cancer: nivolumab and ipilimumab combination in the first line therapy 2019 ·SHILAP Revista de lepidopterología ·В. Б. Матвеев, М. И. Волкова, (unknown)	2
10	Modern approaches to kidney cancer immunotherapy 2018 ·Cancer Urology ·Н. Е. Кушлинский, М. В. Фридман, Alexei Morozov, Е. С. Герштейн, (unknown), В. Б. Матвеев	13
11	Lenvatinib in combination with everolimus in metastatic renal cell carcinoma resistant to antiangiogenic targeted therapy: an initial Russian experience 2018 ·Cancer Urology ·М. И. Волкова, (unknown), (unknown), В. Б. Матвеев	0
12	Resection of the inferior vena cava in patients with renal cell carcinoma with bulky tumor venous thrombosis 2018 ·Cancer Urology ·(unknown), В. Б. Матвеев, М. И. Волкова, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	2
13	MOLECULAR EPIDEMIOLOGY OF RENAL CANCER 2018 ·Cancer Urology ·Давид Заридзе, Anush Mukeriya, Oxana Shangina, В. Б. Матвеев	4
14	Sorafenib is the first targeted agent to treat metastatic kidney cancer 2015 ·SHILAP Revista de lepidopterología ·В. Б. Матвеев, (unknown)	1
15	Molecular features of renal cell carcinoma: early diagnostics and perspectives for therapy 2015 ·SHILAP Revista de lepidopterología ·О. В. Ковалева, (unknown), В. Б. Матвеев, Alexei Gratchev	0
16	RETROPERITONEAL LYMPH NODE DISSECTION AFTER INDUCTION CHEMOTHERAPY IN METASTATIC TESTICULAR NON-SEMINOMA 2014 ·SHILAP Revista de lepidopterología ·В. Б. Матвеев, (unknown), М. И. Волкова, (unknown), (unknown)	1
17	SEQUENTIAL TARGETED THERAPY FOR DISSEMINATED KIDNEY CANCER 2014 ·SHILAP Revista de lepidopterología ·В. Б. Матвеев, М. И. Волкова	3
18	ANDROGEN DEPRIVATION THERAPY WITH LUTEINIZING HORMONE-RELEASING HORMONE ANTAGONISTS FOR PROSTATE CANCER: BEST DISEASE CONTROL WITH A LOWER RISK OF SIDE EFFECTS. RESULTS OF ANALYSIS OF 6 COMPARATIVE RANDOMIZED PHASE III TRIALS OF DEGARELIX AND LUTEINIZIN 2014 ·SHILAP Revista de lepidopterología ·(unknown), В. Б. Матвеев	2
19	Occupational Trichloroethylene Exposure and Renal Carcinoma Risk: Evidence of Genetic Susceptibility by Reductive Metabolism Gene Variants 2010 ·Cancer Research ·Lee E. Moore, Paolo Boffetta, Sara Karami, Paul Brennan, Patricia Stewart, Rayjean J. Hung, Давид Заридзе, В. Б. Матвеев, Vladimír Janout, Helena Kollárová, Vladimír Bencko, Marie Navrátilová, Neonila Szeszenia‐Dąbrowska, Dana Mateș, Jan Gromiec, Ivana Holcátová, Maria J. Merino, Stephen J. Chanock, Wong‐Ho Chow, Nathaniel Rothman	85
20	Screening of prostate cancer. Is it needed? Russian experience. 2006 ·PubMed ·В. Б. Матвеев	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact